Patents Assigned to University of Texas Systems
  • HPLC-PDA method and uses thereof in phytoestrogen measurement
    Patent number: 11346820
    Abstract: Presented are improved and more sensitive methods for measuring levels of phytoestrogens in a biological sample, and specifically in a human urine sample, employing a High Pressure Liquid Chromatography method, coupled with a photodiode array analysis detection system. Calibration curve preparation for each of a panel of phytoestrogen analytes, including daidzein, equol and genistein, are provided employing techniques that demonstrate greater accuracy and sensitivity of sample level measurement. Clinically applicable techniques suitable for large population scale screening, diet and gut microflora characterization and disease analysis and correlation in human populations, such as in at risk breast cancer populations, through monitoring of phytoestrogen levels, is disclosed.
    Type: Grant
    Filed: December 19, 2019
    Date of Patent: May 31, 2022
    Assignee: The Board of Regents of The University of Texas System
    Inventor: Maria Teresa Aguirre
  • NUCLEAR-DERIVED EXOSOMES AND METHODS OF USE THEREOF
    Publication number: 20220163532
    Abstract: The present invention provides that exosomes from ovarian cancer patients contain nuclear proteins and genomic DNA at an increased proportion. As such, detecting nuclear-derived exosomes provides a method of early detection of ovarian cancer. Furthermore, the level of nuclear-derived exosomes can be monitored over time to assess responsiveness to genotoxic therapy.
    Type: Application
    Filed: March 27, 2020
    Publication date: May 26, 2022
    Applicant: Board of Regents, The University of Texas System
    Inventors: Anil K. SOOD, Akira YOKOI
  • MODULATION OF MOLECULAR MARKERS USING S-EQUOL
    Publication number: 20220160678
    Abstract: The present invention provides methods and compositions for modulating molecular markers, and hence treating or preventing breast cancer (e.g., triple-negative breast cancer) and melanoma with a pharmaceutically effective amount of S-equol or a pharmaceutical composition comprising S-equol. The S-equol may be administered alone or in combination with one or more cytotoxic or immunotherapeutic compound or molecule.
    Type: Application
    Filed: November 24, 2021
    Publication date: May 26, 2022
    Applicant: Board of Regents, The University of Texas System
    Inventors: Rong LI, Bin YUAN, Kate Ida LATHROP
  • TUMOR-SELECTIVE COMBINATION THERAPY
    Publication number: 20220160703
    Abstract: The therapies described herein can be selectively lethal toward a variety of different cancer cell types and cancer conditions in a subject. The combination therapies described herein can be useful for the management, treatment, control, or adjunct treatment of diseases, where the selective lethality is beneficial in immunotherapy, particularly where the disease is accompanied by elevated levels of NQO1. In particular, embodiments where an immunotherapy, such as a heckpoint inhibitor, are combined with a NQO1 bioactivatable drug.
    Type: Application
    Filed: March 18, 2020
    Publication date: May 26, 2022
    Applicants: The Board of Regents of The University of Texas System, Indiana University Research and Technology Corporation, The Board of Trustees of the University of Illinois
    Inventors: Yang-Xin FU, Xiumei HUANG, David BOOTHMAN, Paul J. HERGENROTHER, Xiaoguang LI, Lingxiang JIANG
  • Quantum Secure Clock Synchronization Based On Time-Energy And Polarization Entangled Photon Pairs
    Publication number: 20220166617
    Abstract: Systems and methods for quantum clock synchronization are provided. Various embodiments can use time-energy and polarization entangled photons to securely extract the absolute time difference between two remote clocks. In some embodiments, two parties can each have a source of entangled photons. Each party can detect one member of the pair locally and time stamp the detection time, while the other photon gets sent over a common channel (single optical mode) to the other party where the transmitted photon is detected and time stamped. The time stamp values can be shared over an open authenticated channel and each receiver can run a cross-correlation of the detection times. The authenticity and non-spoofability of the timing signal are ensured if each party does not just perform a simple time of arrival measurement but also incorporate polarization measurements whose joint values constitute a Bell test.
    Type: Application
    Filed: February 11, 2022
    Publication date: May 26, 2022
    Applicant: Board of Regents, The University of Texas System
    Inventors: Antia Lamas-Linares, James Troupe
  • Systems and methods for evaluating the brain after onset of a stroke using computed tomography angiography
    Patent number: 11341647
    Abstract: In one embodiment, a patient's brain is evaluated after onset of a stroke by capturing computed tomography angiography (CTA) images of the brain, analyzing the CTA images with a CTA image analysis program to evaluate the patient's brain, and generating results based upon the analysis that provide an assessment of the brain. In some cases, the CTA image analysis program comprises a machine-learning algorithm that has been trained on the results of perfusion imaging analysis.
    Type: Grant
    Filed: September 16, 2019
    Date of Patent: May 24, 2022
    Assignee: The Board of Regents of the University of Texas System
    Inventors: Sunil A. Sheth, Luca Giancardo, Sean I. Savitz
  • SMALL MOLECULE GRB2 STABILIZERS FOR RAS MAP KINASE INHIBITION
    Publication number: 20220151991
    Abstract: The present disclosure compounds of the formula (I-A) or (I), wherein the variables are defined herein, as well as pharmaceutical compositions thereof. The present disclosure also provides methods for the use of said compounds and/or pharmaceutical compositions, such as in the treatment of cancer. The present disclosure also provides methods for the use of compounds of the formula (III), wherein the variables are defined herein.
    Type: Application
    Filed: March 13, 2020
    Publication date: May 19, 2022
    Applicants: Board of Regents, The University of Texas System, Board of Trustees of the University of Arkansas
    Inventors: Zamal AHMED, John A. TAINER, Darin E. JONES
  • Treatment of aberrant fibroblast proliferation
    Patent number: 11331333
    Abstract: Provided is a method of preventing, treating or delaying progression of a disease involving aberrant fibroblast proliferation. The method involves using a compound that reduces the level of tyrosine phosphatase activity effected by the protein EYA1A in the parenchymal organ, a nucleic acid ligase IV inhibitor, or an antisense oligonucleotide against the p53-binding protein 1 (53BP1).
    Type: Grant
    Filed: November 8, 2019
    Date of Patent: May 17, 2022
    Assignees: Georg-August-Universität Göttingen Stiftung Öffentichen Rechts, Universitätsmadizin, Board of Regents, The University of Texas System
    Inventors: Michael Zeisberg, Elisabeth Zeisberg, Bjoern Tampe, Gerhard Anton Mueller, Xu Xingbo, Desiree Tampe, Raghu Kalluri
  • Microbubble and nanobubble expansion using perfluorocarbon nanodroplets for enhanced ultrasound imaging and therapy
    Patent number: 11334993
    Abstract: The disclosure describes imaging and therapy techniques comprising nanodroplets. More particularly, aspects of the disclosure relate to the use of nanodroplets to modify nanobubbles or microbubbles to provide improved imaging and/or therapeutic techniques and compositions.
    Type: Grant
    Filed: February 24, 2020
    Date of Patent: May 17, 2022
    Assignee: The Board of Regents of The University of Texas System
    Inventors: Robert F. Mattrey, Caroline De Gracia Lux, Jacques Lux, Zhenghong Gao, Carlos J. Brambila
  • COMPOUNDS WITH ANTI-TUMOR ACTIVITY AGAINST CANCER CELLS BEARING EGFR OR HER2 EXON 20 INSERTIONS
    Publication number: 20220143023
    Abstract: The present disclosure provides methods of treating cancer in a patient determined to have an EGFR and/or HER2 exon 20 mutation, such as an insertion mutation, by administering a third-generation tyrosine kinase inhibitor, such as poziotinib or afatinib.
    Type: Application
    Filed: March 27, 2020
    Publication date: May 12, 2022
    Applicant: Board of Regents, The University of Texas System
    Inventors: Jacqulyne ROBICHAUX, Monique NILSSON, John V. HEYMACH
  • LILRB4-BINDING ANTIBODY AND METHODS OF USE THEREOF
    Publication number: 20220144944
    Abstract: Provided herein are LILRB4-binding antibodies and methods of treating cancer by administering the LILRB4-binding antibodies alone or in combination with other therapies. Recombinant polypeptides comprising the CDRs of LILRB4-binding antibodies are also provided.
    Type: Application
    Filed: March 2, 2020
    Publication date: May 12, 2022
    Applicant: Board of Regents, The University of Texas System
    Inventors: Naveen SHARMA, James P. ALLISON
  • METHODS OF USING IMIPRIDONES
    Publication number: 20220143024
    Abstract: Provided herein are methods of using ClpP levels and mutation status as a marker for the selection and treatment of cancer patients who will respond to the administration of imipridones. Also provided are methods of treating patients having Perrault syndrome. Also provided are methods of killing bacterial cells and treating bacterial infections using imipridones.
    Type: Application
    Filed: February 21, 2020
    Publication date: May 12, 2022
    Applicants: Board of Regents, The University of Texas System, University Health Network
    Inventors: Michael ANDREEFF, Jo ISHIZAWA, David SCHIMMER, Sara ZARABI
  • COMPOUNDS AND METHODS FOR THE TREATMENT OF PKR-ASSOCIATED DISEASES
    Publication number: 20220143030
    Abstract: Provided herein are RNA-dependent protein kinase (PKR)-associated compounds for the treatment of PKR-associated disorders including cancer, neurodegenerative diseases, and inflammatory conditions.
    Type: Application
    Filed: February 7, 2020
    Publication date: May 12, 2022
    Applicant: Board of Regents, The University of Texas System
    Inventors: Apar PATAER, Bulent OZPOLAT, Stephen G. SWISHER, Ruping SHAO
  • Atmospheric water harvesting system
    Patent number: 11326327
    Abstract: Disclosed herein are water harvesting networks. The harvesters allow extraction and collection of moisture from the atmosphere without requiring electrical energy inputs.
    Type: Grant
    Filed: February 9, 2018
    Date of Patent: May 10, 2022
    Assignee: Board of Regents, The University of Texas System
    Inventors: Guihua Yu, Fei Zhao, Xingyi Zhou
  • Method for fabricating a hyperbolic metamaterial having a near-zero refractive index in the optical regime
    Patent number: 11329389
    Abstract: A method for fabricating a hyperbolic metamaterial coating having a near-zero refractive index is disclosed. The direction of propagating light changes by means of generating subwavelength structures that alter the coatings permittivity and permeability. The coating can be deposited on lenses or incorporated into optical devices. This type of metamaterial can be utilized to direct light towards sensors or to collect light efficiently.
    Type: Grant
    Filed: July 24, 2019
    Date of Patent: May 10, 2022
    Assignee: Board Of Regents, The University of Texas System
    Inventors: Nantakan Wongkasem, Andres Ochoa
  • Small molecule inducers of autophagy
    Patent number: 11325898
    Abstract: Small molecule disruptors of Beclin-1/Bcl-2 protein-protein interactions induce autophagy and hence are useful for treating a variety of indications where stimulation of autophagy is therapeutically useful, including cancer, infection immunity, neurodegeneration, longevity.
    Type: Grant
    Filed: December 4, 2020
    Date of Patent: May 10, 2022
    Assignee: Board of Regents, The University of Texas System
    Inventors: Jef De Brabander, Qiren Liang, Beth Levine, Wei-Chung Chiang
  • Method and system for using logarithm of power feedback for extremum seeking control
    Patent number: 11327448
    Abstract: The present disclosure provides a method and system for optimizing a control process. The method and system comprise using a sensor to generate a feedback signal that represents a measured performance index for an extremum seeking control (ESC) method and sending the feedback signal to an ESC conditioning circuit that applies a logarithmic transformation to the feedback signal to obtain a modified feedback signal. An ESC controller applies the modified feedback signal to the ESC method to generate an output value that is used to control an actuator to maximize the performance of a machine or process.
    Type: Grant
    Filed: May 30, 2018
    Date of Patent: May 10, 2022
    Assignee: Board of Regents, The University of Texas System
    Inventor: Mario A. Rotea
  • ISOLATION AND DETECTION OF EXOSOME-ASSOCIATED MICROBIOME FOR DIAGNOSTIC AND THERAPEUTIC PURPOSES
    Publication number: 20220137056
    Abstract: The present invention provides methods of predicting, diagnosing, and prognosing disease in a patient by analyzing the microbiome signature present in isolated exosomes. In one embodiment, provided herein are methods of detecting a microbiome in a patient, the method comprising: (a) obtaining a body fluid sample from a patient; (b) isolating an exosomes fraction of the body fluid sample; and (c) detecting a microbial macromolecule present in the exosomes fraction.
    Type: Application
    Filed: February 7, 2020
    Publication date: May 5, 2022
    Applicant: Board of Regents, The University of Texas System
    Inventor: Raghu KALLURI
  • ANTISENSE ANTIBACTERIAL COMPOUNDS AND METHODS
    Publication number: 20220135973
    Abstract: Provided are antisense oligomers targeted against bacterial mRNAs and other macromolecules associated with a biochemical pathway and/or cellular process, and related compositions and methods of using the oligomers and compositions to treat an infected mammalian subject, for example, as primary antimicrobials or as adjunctive therapies with classic antimicrobials.
    Type: Application
    Filed: October 12, 2021
    Publication date: May 5, 2022
    Applicants: Board of Regents, The University of Texas System, Oregon State University
    Inventors: David GREENBERG, Bruce L. GELLER
  • COMPOSITIONS AND METHODS FOR ORGAN SPECIFIC DELIVERY OF NUCLEIC ACIDS
    Publication number: 20220133637
    Abstract: The present disclosure provides compositions which shown preferential targeting or delivery of a nucleic acid composition to a particular organ. In some embodiments, the composition comprises a steroid or sterol, an ionizable cationic lipid, a phospholipid, a PEG lipid, and a permanently cationic lipid which may be used to deliver a nucleic acid.
    Type: Application
    Filed: January 10, 2022
    Publication date: May 5, 2022
    Applicant: The Board of Regents of The University of Texas System
    Inventors: Qiang CHENG, Tuo WEI, Daniel J. SIEGWART